Royal Bank of Canada
RLMD icon

Royal Bank of Canada’s Relmada Therapeutics RLMD Stock Holding History

Royal Bank of Canada’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,000
Closed -$770K – 7644
2020
Q4 		$770K Buy
24,000
+400
+2% +$13.7K ﹤0.01% 3744
2020
Q3 		$888K Buy
+23,600
New +$912K ﹤0.01% 3364

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Royal Bank of Canada's RLMD Position: Q1 2026 in Review

Royal Bank of Canada reduced its Relmada Therapeutics (RLMD) stake by 95% in Q1 2026, selling an estimated $9.2K and leaving 95 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6940.

Royal Bank of Canada first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $326K in Q1 2021. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Royal Bank of Canada held 95 shares of Relmada Therapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 1,944 Relmada Therapeutics shares in Q1 2026, an estimated $9.2K.
  • Relmada Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6940 holding.
  • Royal Bank of Canada first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Royal Bank of Canada's Relmada Therapeutics position peaked at $326K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.